As the falsified medicines directive is set to come into full force early next year, Christian Taylor, serialisation business consultant, Zetes, looks at the key challenges and practical questions relating to achieving compliance in more detail.
Questions
The falsified medicines directive (FMD) 2011/62/EU will come into full force on 9 February 2019. With approximately 1% of medicines sold in developed markets being counterfeit, the global counterfeit drug market is worth $200 billion a year.1The legislation aims to prevent counterfeit or unauthorised prescription medicine entering the legal supply chain, providing greater protection for patients.